Clinical trials: Depressive State
Postpartum Depression
A Six-Month Prospective Follow-Up Study of WB001
This study is a 6-month follow-up study to WB001-001 conducted to assess and evaluate the durability of the effect of {WB001+TAU} beyond the 8-week treatment period.
- Trial name
- NCT05693792
- Testing
- Observational
- Sponsor
- Woebot Health
Stable Angina Pectoris Associated With Depression
The Efficacy and Safety of Ginkgo Biloba Dropping Pills in the Treatment of Coronary Heart Disease With Stable Angina Pectoris and Depression
To evaluate the clinical efficacy of Ginkgo biloba dropping pills on improving the frequency of angina pectoris and the life quality of patients with stable angina pectoris and depression symptoms on the basis of the best western…
- Trial name
- NCT04529148
- Testing
- Ginkgo biloba dropping pills，best western medicine treatment, Mimetic drug of ginkgo biloba dropping pills，best western medicine treatment
- Where
- 4 sites in China
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Wanbangde Pharmaceutical Group Co., LTD
Arrhythmia, Quality of Life
Psychosomatic Effects of Implantable Cardioverter Defibrillator With Home Monitoring Function (QUANTUM)
Quality of life (QOL) and psychological well-being of patients with implantable cardioverter-defibrillators (ICDs) are significantly influenced by the experience of shock therapies.
- Trial name
- NCT00325221
- Testing
- HM on, HM Off
- Where
- 7 sites in Austria, Germany and 1 more
- Volunteers
- 148 people
- Sponsor
- Biotronik SE & Co. KG
Major Depressive Disorder
Antidepressant Incomplete Response Depression
Observational, non-interventional, longitudinal, prospective,multicenter, open label (No treatment is involved). 3 assessment will be carried out .
- Trial name
- DRIA (NCT00782964)
- Where
- 48 sites in Spain
- Volunteers
- 364 people
- Sponsor
- AstraZeneca
Weight Loss, Mood
Effects of Lactobacillus Plantarum KABP-51 Probiotic on Body Composition, Microbiome and Mood in Healthy Overweight Adults
The objective of this study is to recruit 60 healthy moderately overweight subjects to participate in a research study investigating the effects of a specific probiotic strain (Lactobacillus plantarum KABP-51) on measures of…
- Trial name
- NCT06808061
- Testing
- Lactobacillus plantarum
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- 3 Waves Wellness
Major Depression
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
The study evaluates the ABCB1-genotype dependent efficacy of a quick dose-escalation strategy within 28 days of treatment with approved antidepressants that are known substrates of the P-glycoprotein, an efflux pump of the…
- Trial name
- NCT02237937
- Testing
- Paroxetine, Sertraline, Citalopram
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- HolsboerMaschmeyer NeuroChemie GmbH
Major Depressive Disorder
Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder
This study investigates two different approaches to the change in antidepressant treatment when an initial treatment is not effective: early intervention or delayed intervention. Two hypothesis will be tested: 1.
- Trial name
- NCT00810069
- Testing
- Duloxetine Hydrochloride, Escitalopram
- Where
- 60 sites in Denmark, France and 9 more
- Volunteers
- 840 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy, safety and tolerability of Levomilnacipran ER for the treatment of fatigue associated with major depressive disorder (MDD).
- Trial name
- NCT01254305
- Testing
- Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine.
- Where
- 20 sites in United States
- Volunteers
- 262 people
- Sponsor
- Forest Laboratories
Treatment Resistant Depressive Disorder
A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of intranasal HS-10345 (84mg) compared with placebo in participants with treatment-resistant depression (TRD).
- Trial name
- NCT05196971
- Testing
- HS-10345 84mg
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Depression, Anxiety
Comparing Message-based Psychotherapy to Once-weekly, Video-based Psychotherapy for Moderate Depression and Anxiety
This study is concerned with evaluating an innovative care delivery platform that is becoming widely available but has not been adequately evaluated in a clinical trial.
- Trial name
- NCT05467787
- Testing
- Message-based psychotherapy (MBP), Video-chat Psychotherapy (VCP)
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Talkspace
Depressive Disorder, Major
A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder
A Placebo Controlled Study Evaluating Efficacy And Safety of Medication In Patients With Major Depressive Disorder (MDD)
- Trial name
- NCT00048204
- Testing
- GW597599B, paroxetine
- Volunteers
- 372 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder
All subjects completing the randomized treatment period in Protocol NS2014-1 will discontinue study drug and be asked to provide consent to be followed in this 6-month study, at their final safety visit.
- Trial name
- NCT02724735
- Testing
- NSI-189
- Where
- 12 sites in United States
- Volunteers
- 220 people
- Sponsor
- Neuralstem Inc.
Post-traumatic Stress Disorder, Depression
Evaluation of Psilocybin-Assisted Psychotherapy in Treating Severe Depression in Patients With PTSD
Post-Traumatic Stress Disorder (PTSD) is a mental disorder that may develop in people who have been exposed to a traumatic event, including actual or threatened death, serious injury, or sexual violence.
- Trial name
- SUMMIT-90 (NCT06141876)
- Testing
- APEX-002-A02
- Volunteers
- 160 people
- Sponsor
- Apex Labs Ltd.
Premenstrual Syndrome (PMS)
Oxaloacetate Supplementation for Emotional PMS
Emotional Premenstrual Syndrome (PMS) affects millions of women worldwide. For Emotional PMS, including depression, anxiety, perceived stress and aggression, there are very few options.
- Trial name
- OAA4PMS (NCT03509714)
- Testing
- Jubilance (100 mg Oxaloacetate/150 mg Ascorbic Acid)
- Volunteers
- 48 people
- Sponsor
- Terra Biological LLC
Postpartum Depression
A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 micrograms per kilogram per hour (μg/kg/h) for 60 hours reduces depressive symptoms in participants with severe postpartum…
- Trial name
- NCT02942004
- Testing
- SAGE-547 60 μg/kg/h, SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 138 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Depression
Bioequivalency Study of Sertraline Under Fasting Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Sertraline Tablets, 100 mg, to Zoloft® Tablets, 100 mg (Pfizer) under fasting conditions using a single-dose, 2-treatment, 2-period, crossover design.
- Trial name
- NCT00602849
- Testing
- Sertraline
- Where
- Canada
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Depressive Disorder, Major
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression
This study is open to adults with depression (major depressive disorder) for whom standard treatment with antidepressants alone does not work sufficiently.
- Trial name
- NCT04521478
- Testing
- BI 1358894, Quetiapine
- Where
- 120 sites in United States, Argentina and 12 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Depression
Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression
The purposes of this study are to determine: The safety of duloxetine and any side effects that might be associated with it. How duloxetine compares to escitalopram and placebo (an inactive ingredient)
- Trial name
- NCT00073411
- Testing
- duloxetine, escitalopram
- Where
- United States
- Volunteers
- 675 people
- Sponsor
- Eli Lilly and Company
Depression
Bioequivalency Study of Protriptyline 10 mg Tablets Under Fasted Conditions
The objective of this study was to prove the bioequivalence of Protriptyline 10 mg tablets under fasted conditions
- Trial name
- NCT00754962
- Testing
- protriptyline
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Treatment-resistant Depression
A Trial of GH001 in Patients With Treatment-resistant Depression
The aim of this randomized, double-blind, placebo-controlled, phase 2b clinical trial is to investigate the safety and efficacy of GH001 (containing mebufotenin [5-methoxy-N,N-dimethyltryptamine; 5-MeO-DMT]) in patients with…
- Trial name
- NCT05800860
- Testing
- GH001
- Where
- 11 sites in Czechia, Germany and 4 more
- Volunteers
- 81 people
- Sponsor
- GH Research Ireland Limited